NCT05838950 · Syracuse University
HIIT Effects on Cardiometabolic Health
What this study is about
The primary aim of this randomly assigned clinical trial is to compare the effects of three different HIIT protocols and a control group on cardiometabolic health in young adults with obesity. Participants will be randomly assigned to one of the following three groups, with each having varying work-to-rest ratios: 1) HIIT-A, 2) HIIT-B, 3) HIIT-C, and 4) control group.
View original scientific description
The primary aim of this randomized clinical trial is to compare the effects of three different HIIT protocols and a control group on cardiometabolic health in young adults with obesity. Participants will be randomly assigned to one of the following three groups, with each having varying work-to-rest ratios: 1) HIIT-A, 2) HIIT-B, 3) HIIT-C, and 4) control group. HIIT-A, HIIT-B, and HIIT-C groups will participate in six sessions of a running based HIIT program over a 2-week training period. Pre-clinical markers of cardiovascular disease, blood lipids and fasting glucose will be measured at the following three time points: baseline, post-intervention, and 2 weeks after the training cessation (i.e., measure for detraining effect). All measurements will be performed three days before the training program and three days after the intervention to avoid the effect of the last training session. Afterwards, the detraining test will be measured 2 weeks post intervention.
Interventions
OTHER
high-intensity interval training intervention
Intervention groups include 3 arms with 3 different HIIT protocols to identify optimal exercise regimen for improving cardiometabolic health in young adults with obesity.
Primary outcome measures
Height
Time frame: Baseline
Height (cm)
Weight
Time frame: Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)
Weight (kg); Change from Baseline weight at 2 week and 4 week
Body mass index
Time frame: Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)
Body mass index (kg/m2); Change from Baseline BMI at 2 week and 4 week
Percentage body fat
Time frame: Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)
Percentage body fat (kg); Change from Baseline percentage body fat at 2 week and 4 week
Fat mass
Time frame: Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)
Fat mass (kg); Change from Baseline fat mass at 2 week and 4 week
Lean mass
Time frame: Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)
Lean mass (kg); Change from Baseline lean mass at 2 week and 4 week
Systolic blood pressure
Time frame: Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)
Systolic blood pressure (SBP, mmHg); Change from Baseline SBP at 2 week and 4 week
Diastolic blood pressure
Time frame: Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)
Diastolic blood pressure (DBP, mmHg); Change from Baseline DBP at 2 week and 4 week
Mean arterial pressure
Time frame: Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)
Mean blood pressure (MAP, mmHg); Change from Baseline MAP at 2 week and 4 week
Flow-mediated dilation
Time frame: Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)
Flow-mediated dilation (FMD, mm); Change from Baseline FMD at 2 week and 4 week
Carotid-femoral Pulse Wave Velocity (cPWV)
Time frame: Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)
cPWV (m/s); Change from Baseline cPWV at 2 week and 4 week
Total cholesterol
Time frame: Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)
Total cholesterol (mg/dl); Change from Baseline TC at 2 week and 4 week
LDL-C
Time frame: Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)
LDL-C (mg/dl); Change from Baseline LDL-C at 2 week and 4 week
HDL-C
Time frame: Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)
HDL-C (mg/dl); Change from Baseline HDL-C at 2 week and 4 week
Triglycerides
Time frame: Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)
Triglycerides (TG, mg/dl); Change from Baseline TG at 2 week and 4 week
Glucose
Time frame: Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)
Glucose (mg/dl); Change from Baseline glucose at 2 week and 4 week
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Young adults with obesity (Age 18 to 25 years old, BMI ≥ 30 kg/m2).
Exclusion criteria
- Syndromic obesity; 1) Any clinical symptoms including cognitive delay, 2) abnormalities in body structure(s), 3) organ-specific abnormalities (kidney, liver failure, excessive eating, and/or other signs of hypothalamic dysfunction such as fatigue, weakness and/or lack of interest in activities.
- Taking weight loss medication(s)
- Currently enrolled (or within previous 6 months) in a weight loss program;
- An underlying disease/medications (steroids, second generation psychotropic agents, hormonal contraception, statins, antihypertensive and antidiabetic medications) that could influence carbohydrate or lipid metabolism.
- Presence of cardiac pacemaker.
- Current or anticipated participation in another research that would interfere with any of the outcomes.
- Current or anticipated pregnancy.
Where
- Syracuse, New York
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jul 23, 2025 · Source of record for eligibility and locations